Evaluating the sensitivity of hybridization-based epigenotyping using a methyl binding domain protein by Shatova, Tatyana A. et al.
Analyst
www.rsc.org/analyst
ISSN 0003-2654
COMMUNICATION
Hadley D. Sikes et al.
Evaluating the sensitivity of hybridization-based 
epigenotyping using a methyl binding domain protein 
Volume 139 Number 15 7 August 2014 Pages 3647–3812
Analyst
COMMUNICATION
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
pr
il 
20
14
. D
ow
nl
oa
de
d 
on
 3
0/
04
/2
01
5 
17
:4
4:
37
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View IssueaDepartment of Chemical Engineering, M
Cambridge, MA 02129, USA. E-mail: sikes@
bDepartment of Chemistry, Kyungpook Natio
† Electronic supplementary informa
10.1039/c4an00667d
Cite this: Analyst, 2014, 139, 3695
Received 14th April 2014
Accepted 28th April 2014
DOI: 10.1039/c4an00667d
www.rsc.org/analyst
This journal is © The Royal Society of CEvaluating the sensitivity of hybridization-based
epigenotyping using a methyl binding domain
protein†
Brandon W. Heimer,a Tatyana A. Shatova,a Jungkyu K. Lee,b Kaja Kaastrupa
and Hadley D. Sikes*aHypermethylation of CpG islands in gene promoter regions has been
shown to be a predictive biomarker for certain diseases. Most current
methods for methylation proﬁling are not well-suited for clinical
analysis. Here, we report the development of an inexpensive device
and an epigenotyping assay with a format conducive to multiplexed
analysis.Introduction
Accurately diagnosing and characterizing cancer is critical to
improving patient outcomes. Medical research coupled with
analytical tests has started to allow physicians to identify
cohorts of patients and deliver therapy developed for their
particular needs. For example, markers such as BRCA1 and
HER2 are routinely used for screening, prognosis, or treatment
selection.1 In addition to somatic mutations, research over the
past decade has shown that epigenetic disruptions in gene
expression, particularly tumor suppressors, can lead to
neoplastic disease.2 Current indications show it is likely the FDA
will soon evaluate DNA methylation proles, specically in the
context of the genes PITX2 (ref. 3) (breast cancer) and SEPT9
(ref. 4) (colon cancer), for use as cancer biomarkers because
such diagnostics have the potential to provide additional
information to that available from the current methods used in
the clinic.
In mammals, enzymatic methylation of the cytosine base
occurs only in the context of the dinucleotide sequence CpG,
that is, when cytosine is sequentially followed by guanosine on
the same DNA strand.2 The human genome has short stretches
of DNA with a high density of CpG dinucleotides termed “CpG
islands.” Many CpG islands are coincident with gene
promoters.5 These CpGs are usually unmethylated.6However, inassachusetts Institute of Technology,
mit.edu
nal University, Daegu, South Korea
tion (ESI) available. See DOI:
hemistry 2014colorectal cancer, human mutL homolog 1 (hMLH1) promoter
hypermethylation has been shown to contribute to genetic
hypermutability as a consequence of inactivated DNAmismatch
repair function.7 Others have correlated promoter hyper-
methylation to patients' responsiveness to select chemothera-
peutics. For example, a subset of glioblastoma patients with
silenced O6-methylguanine DNA methyltransferase (MGMT) is
particularly responsive to treatment with alkylating agents
because there is no active enzyme to remove alkyl adducts from
DNA.8 CpG island hypermethylation has further been shown to
be unique to the tissue of origin9 which adds to the promise of
DNA hypermethylation proles as cancer biomarkers.
Methylation-specic PCR10 is the de facto standard for
methylation proling in diagnostic settings where the genes of
interest are known. Methylation-specic PCR, however, requires
sodium bisulte conversion of unmethylated cytosine bases to
urasil in the target DNA. Chemical conversion is costly, and the
reaction alone requires 12–16 h. Methods must be assiduously
optimized to minimize incomplete deamination of unmethy-
lated cytosine bases and inappropriate conversion of methyl-
ated ones to thymine; both errors can lead to inaccurate
results.11 The degenerate genomic sequence following conver-
sion can also constrain the primer sequence used for down-
stream PCR amplication.12 Further, readout is not direct. The
converted DNAmust be amplied using a separate PCR reaction
for each CpG interrogated and analyzed by gel electrophoresis
making it unsuitable for multiplexing. Luo et al. proposed an
alternative in which a methyl binding domain (MBD) protein
facilitates detection.13 However, this format necessitates not
only the bisulte conversion and PCR steps required for
methylation-specic PCR but also enzymatic remethylation of
the DNA. Recently, Yu et al. reported using surface plasmon
resonance (SPR) to detect MBD binding to methylated DNA.14
While requiring fewer steps, this method is also less amenable
to multiplexed detection and the reliance on ProteOn™ GLC
Sensor Chips (BioRad) signicantly increases the cost per test.
Here, we report the development of a simple method for
detecting methylated DNA fragments from the MGMT geneAnalyst, 2014, 139, 3695–3701 | 3695
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View Article Onlinepromoter. A dening feature is that target oligonucleotides
from the test sample hybridize directly to capture probes prin-
ted in 300 mmdiameter spots on an inexpensive biochip without
requiring bisulte conversion. We detect methylated DNA
duplexes using an MBD protein engineered to facilitate detec-
tion using either uorescence or photopolymerization-based
signal amplication with short reaction times.15Fig. 2 (a) Biochips were spotted with capture probe ssDNA oligos
having two (omm), one (omo), or no (ooo)methylated CpGs in order to
epigenotype the target oligos. Unmethylated ssDNA served as the
negative control. (b) Schematic representation of the area within each
group of spots following hybridization with 100 nM doubly methylated
(omm) target ssDNA and detection using the scheme shown in Fig. 1.
Fluorescence (c) and colorimetric (d) readout of MBD binding to
methylated DNA.Results and discussion
Our epigenotyping assay follows the scheme shown in Fig. 1.
First, single-stranded, 50-hydrazide modied DNA capture
probes are spotted onto an aldehyde functional biochip
according to the layout illustrated in Fig. 2a. Any remaining
unreacted aldehyde groups are quenched with bovine serum
albumin (BSA). DNA target oligonucleotides in a test sample
then hybridize to the corresponding sequence-specic capture
probes on the biochip. Next, biotinylated MBD proteins bind to
DNA duplexes with symmetrically methylated CpGs. Streptavi-
din functionalized with either eosin (photoinitiator) or Cy3 dye
then transduces MBD binding into a colorimetric or uorescent
readout as depicted in Fig. 2b. For Cy3 labeling, the biochip is
directly scanned to produce the type of image shown in Fig. 2c.
For colorimetric detection, an aqueous polyethylene glycol
diacrylate monomer is polymerized to form hydrogels speci-
cally at the sites with surface-bound eosin when irradiated with
green (522 nm) light for approximately two minutes.15 The
hydrogels become visible to the unaided eye aer staining with
a red dye for two minutes as shown in Fig. 2d.15
Several design choices were key to obtaining the results
presented in Fig. 2. The epigenotyping assay we describe here
uses a standard glass microscope slide coated with an agarose
lm.20 The agarose lm coating, with its 3D surface structure,
shields biomolecules from the charged glass substrate and
provides a solution-like environment conducive for nucleic acid
and protein binding events.22,25 Experimentally, the agarose lm
was essential to our assay because self-assembled monolayer
(SAM) coated glass surfaces, when evaluated, suﬀered from high
nonspecic binding and signals not distinguishable fromFig. 1 Methylated and hydrazide functionalized probe ssDNA oligos
are spotted onto activated agarose coated slides with subsequent
blocking using 1% w/v BSA. Target ssDNA oligos for analysis are
hybridized to the sequence-speciﬁc probes on the biochip. A bio-
tinylated MBD protein is then added to bind methylated CpG dinu-
cleotides followed by streptavidin-Cy3 for ﬂuorescence or
streptavidin-eosin for polymerization readout.
3696 | Analyst, 2014, 139, 3695–3701background; see ESI Fig. S4.† Agarose lm coated surfaces also
benet from being signicantly less expensive than SAMs. The
capture probe oligos were modied with a hydrazide which has
a signicantly higher reactivity toward aldehyde functional
surfaces than primary amines leading to detectable DNA
hybridization at sub-nanomolar concentrations as a result of
the higher probe density;26,27 see ESI Fig. S5.† Each DNA probe
was spotted at 10 mM to saturate the aldehyde functional surface
with capture probe oligonucleotides. Further, we sought to print
the smallest spots (300 mm diameter) that allowed for unaided,
colorimetric readout; such feature size miniaturization has also
been shown to improve surface capture performance.28 The
average surface density of the biotinylated control oligo was
measured to be 900  40 oligos per mm2. When the un- (ooo),
singly- (omo), and doubly-methylated (omm) capture probes
were hybridized with 100 nM complimentary, biotinylated
target oligos, the average surface density of the duplex
decreased slightly to 850  50 duplex per mm2; see ESI Fig. S6†
for further detail. All further binding signals were reported as a
fraction of the capture probe density, assumed equal to
the measured density of biotinylated ssDNA (900  40 oligos
per mm2).
The MBD protein is expressed as a green uorescent protein
(GFP) fusion. In addition to being a uorescent reporter, the
GFP also signicantly improves the soluble yield of the fusion
when induced using the protocol we optimized previously.18 We
further added a 15 amino acid C-terminal AviTag™ (Avidity)This journal is © The Royal Society of Chemistry 2014
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View Article Onlinewith an internal lysine residue which the co-expressed BirA
biotin ligase enzyme biotinylates. Such in vivo biotinylation
greatly simplies MBD production and eliminates the risk of
denaturation and loss of binding activity following chemical
biotinylation which requires organic solvents. The MBD
concentration used in the assay was tuned to maximize signal
from duplex DNA with both singly, and doubly, symmetrically
methylated CpGs and minimize signal from hemi-methylated
(dened as signal from unmethylated (ooo) probe spots
hybridized with methylated (omo or omm) target oligos) and
background signal (dened as signal from unmethylated
ssDNA). Using a MBD concentration of 40 mg mL1 optimized
signal intensity, specicity, and the amount of MBD protein
used per assay (1.6 mg) as shown in ESI Fig. S7;† thus, it was
used for all further experiments. Maintaining a low background
signal is critical for achieving low uorescence signal-to-noise
ratios (SNR). However, the ratio is less critical for the colori-
metric assay because no hydrogels will be formed as long as the
background signal is below the photopolymerization ampli-
cation threshold.22
Nucleic acid hybridization is typically performed under
ineﬃcient, diﬀusion-limited conditions in conventional
microarray experiments.29 Numerous microuidic devices that
use mixing have been reported to improve DNAFig. 3 A microﬂuidic device was mated to the biochip. (a) Diagram of
the microﬂuidic channel etched in PDMS. (b) Supporting glass was
added to the unetched side of the microﬂuidic device, and it was
clamped to the biochip. Inlet and outlet tubing was connected to each
end of the channel, fed into a microcentrifuge tube reservoir, and
passed through a peristaltic pump for recirculation. (c) Comparison of
the signal from static MBD binding to doubly (omm) and singly (omo)
methylated probe ssDNA hybridized with either 100, 10, or 1 nM
doubly (omm) methylated target ssDNA under static or microﬂuidic
conditions. Microﬂuidic hybridization increases the signal from MBD
binding by approximately one-third. (d) Comparison of the signal from
MBD binding under static or 100 mL min1 recycling conditions to
doubly and singly methylated duplexes. The microﬂuidic device does
not improve signal due to a weak dependence of MBD binding on ﬂow
rate and a partial hybridization reaction limit.
This journal is © The Royal Society of Chemistry 2014hybridization.29–31 We fabricated a reusable microuidic device
from PDMS, shown in Fig. 3a, to implement a recirculating
mixing method similar to that described by Lee et al. for the
purpose of improving DNA hybridization as well as standardize
the work ow and provide an assay format suitable for auto-
mation. Consistent with previous reports, hybridizing target
DNA using the microuidic device produced MBD binding
signals approximately one-third higher than those achieved
using static DNA incubation over the times studied; see
Fig. 3c.30 However, experimental results shown in Fig. 3d indi-
cated no similar improvement in the fraction bound using the
ow system for MBD binding.
In order to more completely understand whether convection,
diﬀusion and/or reaction rate were limiting the MBD binding
step for the purpose of improving assay sensitivity, we calcu-
lated both the Peclet and the Damko¨hler numbers for the ow
system.23,24 The Peclet number is ameasure of the importance of
convection relative to diﬀusion. It was found to be 1700 which
implies the presence of a thin (approximately 7 mm) depletion
region of MBD above the binding surface. Any MBD above the
depletion region is swept down the channel without having a
chance to encounter the methylated DNA. This also means the
mass transport toward the binding surface is only weakly
dependent on the ow rate of the system. Furthermore, the
Damko¨hler number, which is a ratio of the intrinsic rate of
reaction to diﬀusion, was calculated to be 0.3 using the deple-
tion region length-scale. Because this value is less but not much
less than unity, the system is only partially reaction-limited. The
predicted weak dependence of MBD binding on ow rate and
the partial reaction limit both seem to explain the equivalent
performance of both systems for the MBD binding step.
The signal from MBD binding versus the concentration of
target ssDNA with two methylated CpG sites (omm) is shown inFig. 4 The limit of quantiﬁcation (deﬁned as the minimum concen-
tration producing a signal greater than that from the unmethylated
(ooo) probe mean plus 10 SDs) for doubly (omm) and singly (omo)
symmetrically methylated DNA duplexes was determined to be 0.3 nM
and 1 nM, respectively. Each sample was on-chip hybridized with
the stated concentration of omm target ssDNA and detected with
40 mg mL1 MBD followed by streptavidin-Cy3 labeling.
Analyst, 2014, 139, 3695–3701 | 3697
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View Article OnlineFig. 4 for capture probes with two, one or no complimentary,
methylated CpG sites. We determined the limit of quantica-
tion for MBD binding to spots with two or one symmetrically
methylated CpG sites using our epigenotyping assay to be 0.3
nM and 1 nM, respectively, as dened by the target concentra-
tion that produces a signal greater than that from the un-
methylated probe plus ten standard deviations.32 Sample size is
the current drawback of the system as the reported sensitivity
requires a larger number of cells than what can be obtained
from a needle biopsy. In a clinical sample, the two MGMT
alleles may be heterozygously methylationed at a CpG dinucle-
otide in the interrogated promoter sequence. All cells in the
population would, however, share this methylation pattern due
to the clonal expansion of tumor cells and heritability of DNA
methylation.33 Therefore, the LOD curve would reside between
the unmethylated (ooo) and singly methylated (omo) curves in
that case.
Conclusions
We have demonstrated a novel method for directly hybridizing
and detecting methylated DNA fragments on a biochip. This
simple method requires less time to perform than the existing
methods which rely on bisulte conversion of unmethylated
cytosine bases, PCR, and/or next-generation DNA sequencing.
Eliminating sodium bisulte treatment further reduces the risk
of DNA degradation and inaccuracies resulting from incom-
plete conversion. Our method is also able to achieve a low cost
per test by using inexpensive test surfaces and a recombinant
MBD protein that can be produced eﬃciently in E. coli. Fluo-
rescence detection requires a microarray scanner for readout;
however, the colorimetric assay requires only a green light
source and digital camera for imaging the visible, stained
hydrogels.
New biochips can easily be customized to interrogate a
specic gene or panel of genes by simply designing unique
capture probes specic to the sequences of interest. Further,
microuidic integration provides continuous delivery of test
solutions, standardizes the assay, and provides a platform well-
suited for automation. Quantitative experimental and theoret-
ical analysis also enables future work to develop technologies
using engineered MBD proteins for single-cell epigenetic
analyses.
Experimental
MBD protein cloning, expression, purication, and
characterization
The biotin acceptor peptide sequence MAGGLNDI-
FEAQKIEWHE was appended to the C-terminal end of the
murine MBD1-green uorescent protein (MBD-GFP) construct14
from Steve Blair's Lab (University of Utah, Salt Lake City) for in
vivo biotinylation by the biotin ligase enzyme BirA. This was
accomplished using PCR-driven overlap extension. In short, we
PCR amplied the MBD-GFP gene from the pET-30b vector
starting 4 bp upstream of the EcoRI restriction site and ending
immediately before the 30 TAA stop codon following the GFP3698 | Analyst, 2014, 139, 3695–3701cDNA. Fwd primer: 50-ATCCGAATTCGATGCCAAAAAAGA-30 (24
nt, GC ¼ 37.5%, Tm ¼ 55.6 C) rev. primer: 50-CTTGTA-
CAGCTCGTCCATGC-30 (20 nt, GC ¼ 55.0%, Tm ¼ 56.0 C)
concurrently, we synthesized the cDNA for the biotin acceptor
sequence from primers designed using the DNAWorks soware
from the NIH.16 The construct began at the 50 end with a 30 bp
sequence complimentary to the end of the GFP cDNA
(ATCACTCCCGGCATGGACGAGCTGTACAAG) followed by the
cDNA for the acceptor sequence, the ochre stop codon, a one
nucleotide spacer “A”, the terminal XhoI restriction site and a 4
nt 30 overhang to facilitate restriction enzyme binding. The
MBD1-GFP PCR product and biotin acceptor construct were
joined using PCR-driven overlap extension.17
Fwd primer: 50-ATCCGAATTCGATGCCAAAAAAGA-30 (24 nt,
GC ¼ 37.5%, Tm ¼ 55.6 C) rev. primer: 50-GGTGCTCGAGTT
TATTCATGCCATTCAATTTTCTGCG-30 (37 nt, GC¼ 43.2%, Tm¼
63.5 C).
The gene structure is shown in ESI Fig. S1.† The pET-30b
vector and PCR product were double digested with EcoRI-HF
and XhoI (New England BioLabs), gel puried, and ligated using
T4 ligase (New England BioLabs). The pET-30b/MBD1-GFP-B
construct was co-transformed with pACYC184/BirA (Avidity)
into chemically competent E. coli BL21 (DE3) cells (New
England BioLabs).
E. coli BL21 (DE3) cells containing both plasmids were
inoculated from a glycerol cell stock into a 14 mL culture tube
(VWR Scientic) containing 5 mL of Difco LB Broth (BD
Biosciences) supplemented with 10 mg mL1 chloramphenicol
(Calbiochem) and 50 mg mL1 kanamycin (Calbiochem) and
grown overnight at 37 C and 250 rpm orbital shaking. These
cells were then subcultured in a 1 L ask containing 250 mL of
TB medium (12 g tryptone (BD Biosciences), 24 g yeast extract
(BD Biosciences), and 4 mL glycerol (BDH Chemicals) dissolved
in 900 mL of 18 MU deionized (DI) water, autoclaved, cooled,
and brought to 1 L with the addition of 100 mL of a sterile
solution of 0.17 M KH2PO4 (Macron Chemicals) and 0.72 M
K2HPO4 (BDH Chemicals) supplemented with 50 mg mL
1
kanamycin and incubated at 37 C and 250 rpm orbital shaking.
When the expression culture reached an OD600 of 0.6, MBD
expression was induced by adding IPTG (Omega Bio-Tek) and
D-Biotin (Sigma-Aldrich) to nal concentrations of 1 mM and
50 mM, respectively, and decreasing the incubator temperature
to 20 C for 16 h.18 Cells were harvested in ve 50 mL conical
tubes (BD Falcon) by centrifuging at 4000g and 4 C for 10 min.
One tube was subsequently lysed with BugBuster HT Protein
Extraction Reagent (EMD Millipore) following the manufactur-
er's instructions. The soluble fraction was separated from
insoluble cell debris by centrifugation at 12 000g for 15 min.
The claried lysate was ltered using Acrodisc PF Syringe Filter
0.8/0.2 (Pall) and loaded onto a 1 mL HisTrap™ Fast Flow
column (GE Healthcare) for purication on an A¨KTA purier
10™ FPLC System (GE Healthcare). The column was equili-
brated and washed with binding buﬀer19 (300 mM NaCl (Mal-
linckrodt Chemicals), 100 mM NaxHxPO4 (Mallinckrodt
Chemicals), 10 mM Tris–HCl (BDH Chemicals), 10 mM 2-mer-
captoethanol (J. T. Baker), and 10 mM imidazole (Alfa Aesar),
pH 8), and MBD protein was eluted using a linear gradient fromThis journal is © The Royal Society of Chemistry 2014
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View Article Online0% to 100% elution buﬀer19 (300 mM NaCl, 100 mM NaxHxPO4,
10 mM Tris–HCl, 10 mM 2-mercaptoethanol, and 250 mM
imidazole, pH 8) over 20 column volumes (CV) followed by a
5 CV isocratic elution at 100% elution buﬀer. The pH of the
binding and elution buﬀers was raised from 7.4 to 8 to elimi-
nate a co-eluting impurity present in our prior expression and
purication work with MBD-GFP fusion proteins.18 The frac-
tions containing only MBD protein were pooled, concentrated,
and buﬀer exchanged into storage buﬀer (1 PBS (AMRESCO),
10% glycerol and 1 mM dithiothreitol (MP Biomedicals)) using
a 30 000 MWCO spin lter (Millipore). MBD concentration was
assayed using the bicinchoninc acid (BCA) protein assay kit –
reducing agent compatible (Thermo Scientic) with BSA stan-
dards. Approximately 1.5 mg of MBD protein was loaded onto a
4–15% SDS-PAGE gradient gel (Bio-Rad) and visualized with
Coomassie Brilliant Blue R250 stain (AMRESCO); see ESI
Fig. S2a.† MBD binding activity to methylated DNA was veried
by electromobility shi assay (EMSA) using the method
described previously;18 see ESI Fig. S2b.† Puried protein was
stored at 80 C in 20 mL single-use aliquots for later use in
methylation proling assays.
Streptavidin mutein matrix (Roche) was used for the nal
polishing aﬃnity chromatography step to remove any MBD
protein not biotinylated in vivo. Roche's batch purication
protocol and 50 mL of resin were used to purify 125 mg of
monobiotinylated MBD aer already being puried using IMAC
as described above. Three elution fractions were collected and
pooled. An UltraCruz™ Micro G-25 (Santa Cruz Biotechnology)
gel ltration spin column was used to remove free biotin
remaining from eluting the biotinylated MBD protein. Pure
MBD was buﬀer exchanged into storage buﬀer as described
above. The nal polishing purication step was not routinely
performed aer it was found not to increase the signal from
MBD binding to methylated DNA in the biochip assay; see ESI
Fig. S3.†Preparing biochip test surfaces
Standard clear glass microscope slides (VWR Scientic) coated
with an aldehyde functionalized agarose lm were prepared
using 2 mL of a 0.2% w/v SeaKem® LE agarose (Lonza) solution
and the method previously described.20 The concentration of
agarose in the lm casting solution was decreased to 0.2% w/v
from 1% reported by Afanassiev et al. to reduce nonspecic
uptake of the eosin Y stain used to visualize the photo-
polymerized hydrogels formed usain PBA detection. The ooo,
omo, and omm probe oligonucleotides previously designed to
capture target DNA sequences from the MGMT promoter14 were
ordered from Integrated DNA Technologies with a 50 hydrazide
functionalization (instead of biotin used by Yu et al.) to facilitate
coupling to the reactive aldehyde groups on the biochip surface.
Additionally, two, 50 nt single-stranded oligonucleotides
(50-CATCACACAACATCACACAACATCACGTATATAAAACGGAAC
GTCGAAGG-30) were designed as controls; both had 50 hydra-
zide functionalization and one had a biotin covalently attached
to the 30 end. Each probe was diluted to 10 mM in 3 SSC buﬀer
(G Biosciences) and spotted at 50% relative humidity accordingThis journal is © The Royal Society of Chemistry 2014to the layout illustrated in Fig. 2a using a GeSiM Nano-Plotter
2.1 equipped with a Nano Tip. Each spot was formed from ten
separate 300 pL depositions. Aer spotting, each biochip was
transferred to a vacuum desiccator for overnight incubation. A
circular, 9 mm diameter isolator well was cut from Scotch 3M
665 tape and aﬃxed to the biochip to dene each test area. Each
biochip was then rinsed under a stream of DI water and blown
dry using compressed nitrogen gas. Biochips ready for testing
were stored in the vacuum desiccator until needed.
Microuidic device fabrication
Microuidic devices were fabricated using photolithography
techniques.21 A 40 0 silicon wafer was coated with a 60 mm thick
layer of SU-8 2050 (MicroChem) and patterned using a 25 400
dpi transparency mask (CAD/Art Services, Inc.). Next, a thin
layer of PDMS (Sylgard 184, Dow Corning) was cast onto the SU-
8 mold and cured for 15 min at 80 C until solid. Then, a sup-
porting glass piece was cut from a standard microscope slide
(VWR Scientic) to be 20 mm  12 mm, and was positioned
over the microuidic channel. The rest of the PDMS was poured
onto the mold and cured for 2 h at 80 C. The PDMS was then
peeled oﬀ and each device was cut out separately. The inlet and
outlet holes were punched using a 1.5 mm ID  1.91 mm OD
Harris Uni-Core Puncher (Ted Pella, Inc.). The microuidic
channel, shown in Fig. 3a, features 2 mm wide inlet and outlet
regions that expand to a 9 mm diameter circular test area. The
channel was designed to be 27 mm long in order to allow for a
standard glass slide (25 mm wide) to be used as an additional
support above the PDMS device; see Fig. 3b. The device was then
positioned above the test area on the biochip slide and clamped
on using standard binder clips (Staples).
Detecting methylated DNA with MBD, uorescence and PBA
To block each test area against nonspecic protein binding,
each isolator well was lled with 40 mL of 1% w/v BSA in 1 PBS
and incubated for 15 min in a humid chamber at ambient
temperature. Excess BSA was then washed away with 1 PBS,
and the entire biochip was submersed in 1 PBS at 4 C for
10 min. Following a rinse with DI water, dilutions of omm
target14 oligonucleotides were prepared in hybridization buﬀer
(6 SSC, 5 Denhardt's (BioExpress)), and 40 mL of each were
pipetted onto separate test areas. Biochips were then incubated
in a humid chamber (dened here as a pipette tip box partially
lled with DI water) for 4 h at ambient temperature to allow for
DNA capture. Each biochip was rinsed with 1 PBS followed by
DI water to remove unhybridized target DNA. Next, 40 mL of
MBD protein diluted in binding buﬀer (20 mM HEPES (EMD
Millipore), pH 7.9, 3 mM MgCl2 (BDH Chemicals), 10% v/v
glycerol, 1 mM dithiothreitol, 100 mM KCl (BDH Chemicals),
0.1% w/v BSA, and 0.01% v/v Tween-20) was pipetted onto each
test area, and the biochip was incubated for 30 min in a humid
chamber at 4 C. Aer MBD incubation, each test site was rinsed
with PBST (1 PBS, 0.1% Tween-20 (Sigma-Aldrich)) followed by
1 PBS, and the entire biochip was submersed in 1 PBS at 4 C
for 25 min. Following a rinse with DI water, 40 mL of 0.1 mM
streptavidin-Cy3 or streptavidin-eosin in 1 PBS, 5Analyst, 2014, 139, 3695–3701 | 3699
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View Article OnlineDenhardt's, and 0.5% w/v BSA was pipetted onto each test area,
and the biochip was incubated for 5 min in a humid chamber
covered in foil at ambient temperature. Unbound labeling
reagent was removed by washing sequentially with PBST, 1
PBS, and DI water followed by blow drying using compressed
nitrogen gas. The biochip was either scanned in the case of
streptavidin-Cy3 uorescent detection or polymerized using an
aqueous PEG diacrylate monomer and methods previously
described.22
Alternatively, the reusable microuidic device was attached
to a rinsed and dried biochip using binder clips. FEP 1/160 0 OD
 0.02000 ID tubing (Upchurch Scientic) was inserted into each
port on the device and mated to 0.89 mm ID Tygon-LFL tubing
(Saint-Gobain) which was then run through a Masterex C/L
77120-52 peristaltic pump (Cole Parmer). All of the tubing
connections were self-sealing, and no glue was necessary. A 1%
w/v BSA in 1 PBS solution was pumped through the micro-
uidic device at 100 mLmin1 for 15 min followed by 1 PBS for
10 min. A solution of omm target ssDNA in 6 SSC/5 Den-
hardt's was recirculated at 100 mL min1 for 4 h. A 1 PBS
solution was pumped through the microuidic device at 100 mL
min1 for 5 min followed by DI water for another 5 min. MBD
protein diluted to 40 mg mL1 in binding buﬀer was recirculated
at 100 mL min1 for 30 min. PBST, 1 PBS, and DI water were
sequentially pumped through the microuidic device for 5 min
each at 100 mL min1. Fluorescent or photoinitiator labeling
and detection was performed as described above.Biochip analysis
Biochips labeled with streptavidin-Cy3 were scanned using a
Molecular Devices GenePix 4000B uorescent microarray
scanner. Each uorescence image was analyzed using ImageJ
(NIH). The mean uorescence intensity for each spot was
determined by adjusting the threshold of the image to include
the entire spot area and averaging the constituent pixel inten-
sities. Fraction bound values were computed by dividing the
average signal from replicate spots by the average signal from
the biotinylated ssDNA control spots. The background corrected
intensity (BCI) was computed by subtracting the mean back-
ground intensity (signal from unmethylated ssDNA) from the
mean uorescence intensity value from replicate spots. Cy3
surface densities were then calculated from BCI values using a
calibration curve generated by scanning and analyzing a Full
Moon Biosystems calibration array. Dividing the Cy3 surface
densities by the known average number of Cy3 dye molecules
per streptavidin produced the surface density of binding events.
Each polymerized test area was imaged using the digital
camera in the ampliPHOX® Reader (InDevR) imaging bay.Quantitative MBD hybridization
analysis
The MBD diﬀusion coeﬃcient (D) was estimated to be 1.1 
1010 m2 (s)1 using the Stokes–Einstein equation. All calcula-
tions used 2.88  106 (M s)1 and 0.4 (s)1 MBD association (ka)
and dissociation (kd) rates, respectively.14 The depletion zone3700 | Analyst, 2014, 139, 3695–3701thickness was approximated as Ld ¼ L(Pes)1/3, where Pes is
dened as the shear Peclet number (Pes¼ 6(L/H)2Pe).23,24 L is the
length of the binding area, which was approximated as 900 mm
(equivalent to three spot diameters), H is the channel height, Pe
is the Peclet number (Pe¼ UH/D), and U is the uid velocity. The
Damko¨hler number (Da¼ kaCsLd/D) was calculated based on the
surface density of DNA duplexes (Cs) in each spot and
the depletion zone thickness (Ld).
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